Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial

The Lancet

Volumn 386, Issue 9992, 2015, Pages 444-451

  Long, Georgina V ^a,b   Stroyakovskiy, Daniil ^c   Gogas, Helen ^d   Levchenko, Evgeny ^e   De Braud, Filippo ^f   Larkin, James ^g   Garbe, Claus ^h   Jouary, Thomas ⁱ   Hauschild, Axel ^j   Grob, Jean Jacques ^k   Chiarion Sileni, Vanna ^l   Lebbe, Celeste ^m   Mandalà, Mario ⁿ   Millward, Michael ^o   Arance, Ana ^p   Bondarenko, Igor ^q   Haanen, John B A G ^r   Hansson, Johan ^s   Utikal, Jochen ^t,u   Ferraresi, Virginia ^v   Kovalenko, Nadezhda ^w   Mohr, Peter ^x   Probachai, Volodymr ^y   Schadendorf, Dirk ^z   Nathan, Paul ^aa   Robert, Caroline ^ab,ac   Ribas, Antoni ^ad   Demarini, Douglas J ^ae   Irani, Jhangir G ^ae   Swann, Suzanne ^ae   Legos, Jeffrey J ^ae   Jin, Fan ^af   Mookerjee, Bijoyesh ^ae   Flaherty, Keith ^ag   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b MATER HOSPITAL   (Australia)

^c Moscow City Oncology Clinical Hospital 62   (Russian Federation)

^d UNIVERSITY OF ATHENS   (Greece)

^e N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ HÔPITAL SAINT ANDRÉ   (France)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k AIX MARSEILLE UNIVERSITY   (France)

^l VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^m INSERM   (France)

ⁿ PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^o SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^p HOSPITAL CLÍNIC   (Spain)

^q Dnipropetrovsk State Medical Academy   (Ukraine)

^r NETHERLANDS CANCER INSTITUTE   (Netherlands)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t UNIVERSITY OF HEIDELBERG   (Germany)

^u GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^v REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^w Volograd Regional Oncology Dispensary 3   (Russian Federation)

^x Elbe Klinikum Stade   (Germany)

^y Dnipropetrovsk Clinical Psychiatric Hospital of Dnipropetrovsk Regional Council   (Ukraine)

^z UNIVERSITY HOSPITAL ESSEN   (Germany)

^aa MOUNT VERNON CANCER CENTRE   (United Kingdom)

^ab INSTITUT GUSTAVE ROUSSY   (France)

^ac UNIVERSITÉ PARIS SACLAY   (France)

^ad UNIVERSITY OF CALIFORNIA   (United States)

^ae NOVARTIS PHARMA AG   (Switzerland)

^af MERCK RESEARCH LABORATORIES   (United States)

^ag MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; PLACEBO; TRAMETINIB; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERY ELDERLY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; GENETICS; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938739283     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60898-4     Document Type: Article

References (16)

1. KT Flaherty, JR Infante, A Daud et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
2. GV Long, D Stroyakovskiy, H Gogas et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 371 2014 1877 1888
3. C Robert, B Karaszewska, J Schachter et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 2015 30 09
4. EA Eisenhauer, P Therasse, J Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
5. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf 2010 (accessed May 7, 2015).
6. KKG Lan, DL DeMets Discrete sequential boundaries for clinical trials Biometrika 70 1983 659 663
7. PC O'Brien, TR Fleming Multiple testing procedures for clinical trials Biometrics 35 1979 549 556
8. FS Hodi, SJ O'Day, DF McDermott et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
9. C Robert, GV Long, B Brady et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
10. J Larkin, PA Ascierto, B Dréno et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 2014 1867 1876
11. K Flaherty, A Daud, JS Weber et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM) J Clin Oncol 32 2014 9010
12. K Flaherty, A Daud, JS Weber et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM) J Clin Oncol 32 5 suppl 2014 abstr 9010.
13. A Ribas, R Gonzalez, A Pavlick et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF-mutated melanoma: a phase 1b study Lancet Oncol 15 2014 954 965
14. C Robert, J Schachter, GV Long et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 2015 10.1056/NEJMoa1503093 published online April 19.
15. AM Menzies, MT Ashworth, S Swann et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial Ann Oncol 26 2015 415 421
16. F Su, A Viros, C Milagre et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215